A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
893estimated
Sites
237
Countries
Argentina, Australia, Austria +23
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-10-04 | actual | When the study began enrolling |
| Primary completion | 2026-02-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Elranatamab — also filed as PF-06863135
- Drug: Daratumumab — also filed as Darzalex Faspro; Darzalex solution for injection
- Drug: Pomalidomide — also filed as Pomalyst, Imnovid
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFPart 1 Safety Lead-In: Incidence of dose limiting toxicities
measured First 42 days after first elranatamab dose
Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria
measured From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 51 months
Part 3: Frequency of treatment-emergent adverse events
measured First 84 days after first elranatamab dose
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed